^
BIOMARKER:

CCDC6-RET fusion

i
Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1, CCDC6, Coiled-Co
Entrez ID:
CCDC6-RET fusion
NSCLC
RET inhibitor
Sensitive: C3 – Early Trials
CCDC6-RET fusion
NSCLC
vandetanib
Sensitive: C3 – Early Trials
CCDC6-RET fusion
NSCLC
crizotinib
Sensitive: C3 – Early Trials
CCDC6-RET fusion
CRC
RXDX-105
Sensitive: C3 – Early Trials
CCDC6-RET fusion
NSCLC
sunitinib
Sensitive: C3 – Early Trials
CCDC6-RET fusion
NSCLC
nintedanib
Sensitive: C3 – Early Trials
CCDC6-RET fusion
NSCLC
cabozantinib capsule
Sensitive: C3 – Early Trials
CCDC6-RET fusion
NSCLC
lenvatinib
Sensitive: C3 – Early Trials
CCDC6-RET fusion
Thyroid Gland Anaplastic Carcinoma
selpercatinib
Sensitive: C4 – Case Studies
CCDC6-RET fusion
NSCLC
RXDX-105
Sensitive: D – Preclinical
CCDC6-RET fusion
LUAD
cabozantinib capsule
Sensitive: D – Preclinical